Nuvalent

Nuvalent banks $166M IPO to push resistance-beating cancer drugs

After taking aim at the customary $100 million IPO, Nuvalent is reeling in $166 million to propel a pair of lung cancer treatments through the clinic.

Amirah Al Idrus Jul 29, 2021 11:20am

Financial documents next to blocks that spell IPO

Nuvalent newest biotech to file for $100M IPO to fund 2 trials

Jul 7, 2021 2:56pm